- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medigene AG
Industry Sector: HealthTechnology
CEO: Selwyn Ho, PhD
Number Of Employees: 86
Enterprise Value: $26,197,655
PE Ratio: -1.26
Exchange/Ticker 1: Xetra:MDG1
Exchange/Ticker 2: N/A
Latest Market Cap: $12,361,599
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Nov 3, 2022
Management Tracks
Fantaccini becomes head of medical affairs, CSO at Novartis
Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Oct 11, 2022
Product Development
Immatics looks to build on momentum for TCR T cell therapy
Company parlays data for PRAME therapy into $110M follow-on
BioCentury | May 13, 2022
Management Tracks
New CEOs at CorMedix, Medigene
Plus updates from Elicio, Rejuvenate, Canbridge and more
BioCentury | Mar 25, 2022
Management Tracks
Emergent appoints Harsanyi, Katkin in board restructuring
Plus Sosei ratifies executive changes and updates from Mesoblast, Creyon and more
BioCentury | Feb 23, 2022
Deals
BioNTech adds to TCR arsenal with Medigene’s PRAME, platforms
The deal includes a switch technology that converts immunosuppressive ligands into costimulatory signals
BioCentury | Mar 25, 2021
Management Tracks
Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more
Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Bart Filius to president from CFO while remaining COO. CEO Onno van de Stolpe will be responsible for oversight of R&D activities. Caroline
BioCentury | Jun 4, 2020
Emerging Company Profile
Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round
The Dutch and Israeli company plans to take pridopidine into pivotal studies for Huntington’s, ALS
Items per page:
1 - 10 of 351